Effectiveness of 11C-choline PET/CT in prostate cancer surveillance.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
; 42(2): 93-99, 2023.
Article
en En
| MEDLINE
| ID: mdl-36427802
ABSTRACT
AIM:
Our aim was to analyse the performance of [11C]choline PET/CT in prostate cancer (PCa) surveillance, especially in patients with prostate specific antigen (PSA)â¯<â¯1â¯ng/mL. MATERIAL ANDMETHODS:
Three hundred and twenty-nine [11C]choline PET/CT examinations from 191 patients (68.2⯱â¯7.2 years) submitted for PCa surveillance or biochemical recurrence were retrospectively evaluated. PSA at study was 13.0⯱â¯84.2â¯ng/mL. Main initial treatment was radical prostatectomy (RP) in 81 patients, and other treatments (radiotherapy, chemotherapy, hormonotherapy) in 110. PET/CT was acquired 20' after injection of 555-740 MBq of [11C]choline. Minimum follow-up was 12 months.RESULTS:
Two hundred and nineteen (66.6%) out of the 329 PET/CT examinations were positive. The percentage of positive examinations was significantly higher in patients with other initial treatment than RP compared to patients with RP (85.6% vs. 43.6%, respectively). One hundred and thirty PET/CT (59.4%) showed local recurrence, 48 (21.9%) distant recurrence, and 41 (18.7%) local plus distant recurrence. Initial therapeutic approach was changed in 139 cases (63.5%). In the subgroup of 81 [11C]choline PET/CT scans performed with PSAâ¯<â¯1â¯ng/mL, 23 (28.4%) showed a positive result. Initial therapeutic approach was changed in 9 (11.1%). Three (4.8%) out of 63 patients died as per PCa.CONCLUSION:
[11C]choline PET/CT demonstrated its effectiveness in PCa surveillance and restaging, even in patients with serum PSAâ¯<â¯1â¯ng/mL. The diagnostic performance was different depending on the initial treatment, been higher in patients with non-surgical treatment.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Tomografía Computarizada por Tomografía de Emisión de Positrones
Tipo de estudio:
Screening_studies
Límite:
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Rev Esp Med Nucl Imagen Mol (Engl Ed)
Año:
2023
Tipo del documento:
Article